secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2022-12-01T23:59:59+00:00
Accession:  0001157523-22-001698
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra announces positive FDA pre-NDA meeting for ADX-2191; NDA submission expected by end of 2022
--------------------------------------------------------------------------------

- Pre-NDA meeting with FDA concluded positively; NDA for ADX-2191 in primary vitreoretinal lymphoma planned as soon as end of 2022.
- Company intends to request Priority Review, which would shorten FDA review to 6 months.
- ADX-2191 has Orphan Drug Designation; Phase 3 GUARD Trial showed no serious adverse events and was well tolerated.
- Most common adverse event was punctate keratitis, less frequent than previously reported with compounded methotrexate.
- Type C meeting for proliferative vitreoretinopathy and Phase 2 retinitis pigmentosa results expected in first half of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000115752322001698/0001157523-22-001698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000115752322001698/a52993162.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-001698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer